The use of generic medication in epilepsy: A review of potential issues and challenges

European Journal of Paediatric Neurology

Volumn 13, Issue 2, 2009, Pages 87-92

  Van Paesschen, Wim ^a   Hauman, Henri ^b   Lagae, Lieven ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Epilepsy Centre   (Belgium)

Author keywords

Antiepileptic drugs; Epilepsy; Generic substitution; Generics; Overview

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GENERIC DRUG; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOEQUIVALENCE; DIPLOPIA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; EPILEPSY; HUMAN; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; SEIZURE;

ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; DRUGS, GENERIC; EPILEPSY; HUMANS; SEIZURES; TREATMENT OUTCOME;

EID: 60749096614     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2008.07.007     Document Type: Article

References (53)

1. Heaney D.C., and Sander J.W. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 6 (2007) 465-468
2. Crawford P., Feely M., Guberman A., and Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15 (2006) 165-176
3. American Pharmaceutical Association. Substitution of critical dose drugs: issues, analysis, and decision making (2000), American Pharmaceutical Association, Washington, DC
4. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25 (2003) 1578-1592
5. Nuwer M.R., Browne T.R., Dodson W.E., et al. Generic substitutions for antiepileptic drugs. Neurology 40 (1990) 1647-1651
6. Feely M., Crawford P., Kramer G., and Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. Eur J Hosp Pharm Sci 11 (2005) 83-87
7. Guberman A., and Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 27 (2000) 37-43
8. European Commission Enterprise Directorate-General. Volume 2A. Proceduresfor marketing authorisation. Chapter 1. Marketing authorisation. Brussels: European Commission Enterprise Directorate-General; 2006.
9. European Parliament. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the community code relating to medicinal products for human use. Strasbourg: European Parliament, 2004.
10. Edelbroek P., Augustijn P., The Haan G., Rademaker M., and Geesink H. Change in oxcarbazepine (Trileptal(R)) formulation is associated with more side effects and higher blood concentrations. J Neurol Neurosurg Psychiatry 71 (2001) 708a-709a
11. Lamy P.P. Generic equivalents: issues and concerns. J Clin Pharmacol 26 (1986) 309-316
12. EUCARE. European White Paper on Epilepsy. Epilepsia 44 Suppl. 6 (2003) 1-88
13. Schmidt D., and Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand 111 (2005) 291-300
14. Jacoby A., Buck D., Baker G., et al. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 39 (1998) 776-786
15. Noeker M., Haverkamp-Krois A., and Haverkamp F. Development of mental health dysfunction in childhood epilepsy. Brain Dev 27 (2005) 5-16
16. Tomson T., Walczak T., Sillanpaa M., and Sander J.W. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 46 Suppl. 11 (2005) 54-61
17. American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 40 (1990) 1641-1643
18. Wilner A.N. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 3 (2002) 522-525
19. Jobst B.C., and Holmes G.L. Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. CNS Drugs 18 (2004) 617-628
20. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 (2004) 995-998
21. Heaney D.C., and Begley C.E. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia 43 Suppl. 4 (2002) 10-16
22. Begley C.E., Famulari M., Annegers J.F., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41 (2000) 342-351
23. Cockerell O.C., Hart Y.M., Sander J.W., and Shorvon S.D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 18 (1994) 249-260
24. Heaney D. Epilepsy at work: evaluating the cost of epilepsy in the workplace. Epilepsia 40 Suppl. 8 (1999) 44-47
25. Crawford P., Hall W.W., Chappell B., Collings J., and Stewart A. Generic prescribing for epilepsy. Is it safe?. Seizure 5 (1996) 1-5
26. Haskins L.S., Tomaszewski K.J., and Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 (2005) 98-105
27. Burkhardt R.T., Leppik I.E., Blesi K., et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 63 (2004) 1494-1496
28. Gilman J.T., Alvarez L.A., and Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 43 (1993) 2696-2697
29. Hartley R., Aleksandrowicz J., Ng P.C., et al. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?. Br J Clin Pract 44 (1990) 270-273
30. Mayer T., May T.W., Altenmüller D.M., Sandmann M., and Wolf P. Clinical problems with generic antiepileptic drugs. Clin Invest Drug 18 (1999) 17-26
31. Welty T.E., Pickering P.R., Hale B.C., and Arazi R. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 26 (1992) 775-777
32. MacDonald J.T. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 37 (1987) 1885
33. Wyllie E., Pippenger C.E., and Rothner A.D. Increased seizure frequency with generic primidone. JAMA 258 (1987) 1216-1217
34. Berg M. What's the problem with generic antiepileptic drugs?. Neurology 68 (2007) 1245-1246
35. Andermann F., Duh M.S., Gosselin A., et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to brand compounds compared to other drug classes. Epilepsia 48 (2006) 464-469
36. LeLorier J., Duh M.S., Paradis P.E., et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70 (2008) 2179-2186
37. Epilepsy Action. Position statement - consistency of supply. Leeds: British Epilepsy Association; 2005.
38. Haymarket Publishing. Mims (2006), Haymarket Publishing Ltd, London
39. Stokes T., Shaw E.J., Juarez-Garcia A., Camosso-Stefinovic J., and Baker R. Clinical guidelines and evidence review for the epilepsys: diagnosis and management in adults and children in primary and secondary care (2004), Royal College of General Practitioners, London
40. MPA (Läkemedelsverket). Substitutable medical products. Uppsala; 2006.
41. MPA (Läkemedelsverket). Neurontin and gabapentin nycomed - why aren't they interchangeable? Uppsala; 2004.
42. The Finnish National Agency for Medicines (Laakelaitos). The National Agency for Medicines' updated (November 2005) principles for the preparation of interchangeable drugs that are authorized for sale; 2005.
43. DMA. Press release. Increasingly stringent requirements for authorisation of substitution for epilepsy medicine. Copenhagen; 2005.
44. Health Canada. Guidance for industry on Bioequivalence critical dose range; modified 2006:06-7. Document available on www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/critical_dose.
45. American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy (2006), American Academy of Neurology, Saint Paul, MN
46. Krämer G. Generic substitution in antiepileptic drug therapy: do new regulations match clinical experience? Congress of the European Federation Abstract Book; 2005.
47. Ligue Française Contre L'Epilepsie. Communiqué la Presse 3 July 2007.
48. Meyer M.C., Straughn A.B., Jarvi E.J., et al. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 9 (1992) 1612-1616
49. Meyer M.C., Straughn A.B., Mhatre R.M., et al. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 15 (1998) 1787-1791
50. Nies A.S. Principles of therapeutics. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. (2001), McGraw-Hill Medical Publishing Division, New York, NY 45-66
51. Silpakit O., Amornpichetkoon M., and Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 31 (1997) 548-552
52. Soryal I., and Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 55 (1992) 688-691
53. Welage L.S., Kirking D.M., Ascione F.J., and Gaither C.A. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc (Wash) 41 (2001) 856-867